Table 2.
Results from Cox regression of overall survival in a Scandinavian population-based cohort of metastatic colorectal cancer patients treated with first-line chemotherapy.
| Variable | Unadjusted | Fully adjusteda (n = 245, e = 230) | |||||
|---|---|---|---|---|---|---|---|
| n/e | HR | 95% CI | p value | HR | 95% CI | p value | |
| Age, years | 280/265 | 1.01 | (1.00, 1.02) | 0.157 | 1.00 | (0.99, 1.02) | 0.971 |
| Female | 280/265 | 0.97 | (0.76, 1.23) | 0.786 | 0.69 | (0.52, 0.92) | 0.010 |
| PS ECOG | 280/265 | 2.24 | (1.62, 3.09) | <0.001 | 2.15 | (1.49, 3.10) | <0.001 |
| Right-sided | 277/262 | 1.19 | (0.93, 1.54) | 0.171 | 0.92 | (0.67, 1.25) | 0.580 |
| Tumour grade 3 | 274/259 | 1.97 | (1.47, 2.64) | <0.001 | 1.59 | (1.11, 2.28) | 0.012 |
| >1 metastatic site | 280/265 | 1.50 | (1.17, 1.91) | 0.001 | 1.39 | (1.04, 1.87) | 0.026 |
| Synchronous metastasis | 280/265 | 0.93 | (0.73, 1.19) | 0.563 | 0.84 | (0.63, 1.11) | 0.216 |
| Secondary metastasis surgery | 279/264 | 0.26 | (0.17, 0.40) | <0.001 | 0.32 | (0.20, 0.53) | <0.001 |
| ALP > UNL | 265/250 | 1.19 | (1.40, 2.35) | <0.001 | 1.83 | (1.37, 2.46) | <0.001 |
| BRAFV600E mutation | 280/265 | 1.69 | (1.24, 2.30) | 0.001 | 1.70 | (1.09, 2.63) | 0.018 |
| KRAS mutation | 271/256 | 0.97 | (0.76, 1.24) | 0.801 | 1.59 | (1.16, 2.19) | 0.004 |
| CDX2 negative | 278/263 | 2.37 | (1.69, 3.33) | <0.001 | 1.70 | (1.10, 2.62) | 0.017 |
| MSI-H | 279/264 | 3.26 | (1.93, 5.50) | <0.001 | 3.37 | (1.63, 6.97) | 0.001 |
| CD3 density | 280/265 | 0.98 | (0.96, 0.99) | 0.031 | 0.97 | (0.95, 0.99) | 0.027 |
| CD68 density | 280/265 | 0.98 | (0.96, 1.00) | 0.063 | 0.99 | (0.96, 1.01) | 0.224 |
| CD8 density | 280/265 | 0.99 | (0.96, 1.01) | 0.311 | n.i. | ||
n number of patients, e number of events, HR hazard ratio, CI confidence interval, p value from likelihood ratio test, PS ECOG performance status score developed by Eastern Cooperative Oncology Group, Right-sided tumour site of colon cancer in ascending colon and transversum, Synchronous metastases within 6 months after initial diagnoses, ALP > UNL alkaline phosphatase above upper normal limit, MSI-H microsatellite instable high, CD3 density square root transformed number of tumour-infiltrating CD3 lymphocytes per mm2 tumour tissue microarray, CD8 density square root transformed number of tumour-infiltrating CD8 lymphocytes per mm2 tumour tissue microarray, CD68 density square root transformed number of tumour-infiltrating CD68 macrophages per mm2 tumour tissue microarray, n.i. not included. p-values < 0.05 typed in bold.
aLDH high was also statistically significant when included in the multiple regression model but was excluded from the analysis due to missing values.